Armin Leitner

1.2k total citations
13 papers, 451 citations indexed

About

Armin Leitner is a scholar working on Genetics, Hematology and Rheumatology. According to data from OpenAlex, Armin Leitner has authored 13 papers receiving a total of 451 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Genetics, 11 papers in Hematology and 8 papers in Rheumatology. Recurrent topics in Armin Leitner's work include Chronic Lymphocytic Leukemia Research (11 papers), Chronic Myeloid Leukemia Treatments (11 papers) and Eosinophilic Disorders and Syndromes (8 papers). Armin Leitner is often cited by papers focused on Chronic Lymphocytic Leukemia Research (11 papers), Chronic Myeloid Leukemia Treatments (11 papers) and Eosinophilic Disorders and Syndromes (8 papers). Armin Leitner collaborates with scholars based in Germany, Switzerland and Belgium. Armin Leitner's co-authors include Andreas Hochhaus, Martin C. Müller, Susanne Saußele, Rüdiger Hehlmann, Claudia Haferlach, Stefan W. Krause, Aloïs Gratwohl, Ulrike Proetel, Nadine Pletsch and Susanne Jung-Munkwitz and has published in prestigious journals such as Journal of Clinical Oncology, Blood and British Journal of Cancer.

In The Last Decade

Armin Leitner

12 papers receiving 445 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Armin Leitner Germany 7 342 303 210 105 57 13 451
Heather A. Bradeen United States 6 262 0.8× 217 0.7× 168 0.8× 65 0.6× 37 0.6× 7 400
Jeiry Filian United States 5 556 1.6× 501 1.7× 346 1.6× 95 0.9× 15 0.3× 7 621
Fabrizio Ciccone Italy 8 460 1.3× 403 1.3× 208 1.0× 81 0.8× 16 0.3× 13 574
Marie Colombat France 2 353 1.0× 249 0.8× 300 1.4× 55 0.5× 42 0.7× 4 488
J. Janssen Netherlands 9 285 0.8× 222 0.7× 111 0.5× 70 0.7× 14 0.2× 11 412
Julian Perez Ronco Switzerland 7 211 0.6× 278 0.9× 130 0.6× 44 0.4× 19 0.3× 15 373
J Score United Kingdom 10 226 0.7× 179 0.6× 218 1.0× 23 0.2× 58 1.0× 13 396
U. Wandl Germany 10 250 0.7× 161 0.5× 88 0.4× 72 0.7× 16 0.3× 26 343
Mona Lisa Alattar United States 6 378 1.1× 191 0.6× 53 0.3× 78 0.7× 25 0.4× 13 487
Arta Dreimane Sweden 9 296 0.9× 246 0.8× 123 0.6× 74 0.7× 5 0.1× 17 347

Countries citing papers authored by Armin Leitner

Since Specialization
Citations

This map shows the geographic impact of Armin Leitner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Armin Leitner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Armin Leitner more than expected).

Fields of papers citing papers by Armin Leitner

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Armin Leitner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Armin Leitner. The network helps show where Armin Leitner may publish in the future.

Co-authorship network of co-authors of Armin Leitner

This figure shows the co-authorship network connecting the top 25 collaborators of Armin Leitner. A scholar is included among the top collaborators of Armin Leitner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Armin Leitner. Armin Leitner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Rosée, Paul La, Philippe Martiat, Armin Leitner, et al.. (2013). Improved tolerability by a modified intermittent treatment schedule of dasatinib for patients with chronic myeloid leukemia resistant or intolerant to imatinib. Annals of Hematology. 92(10). 1345–1350. 36 indexed citations
2.
Hehlmann, Rüdiger, Michael Lauseker, Susanne Jung-Munkwitz, et al.. (2011). Tolerability-Adapted Imatinib 800 mg/d Versus 400 mg/d Versus 400 mg/d Plus Interferon-α in Newly Diagnosed Chronic Myeloid Leukemia. Journal of Clinical Oncology. 29(12). 1634–1642. 218 indexed citations
3.
Giehl, Michelle, Armin Leitner, Claudia Haferlach, et al.. (2010). Detection of centrosome aberrations in disease‐unrelated cells from patients with tumor treated with tyrosine kinase inhibitors. European Journal Of Haematology. 85(2). 139–148. 13 indexed citations
4.
Müller, Martin C., Andreas Hochhaus, Michael Lauseker, et al.. (2010). Molecular Response <1% BCR-ABL IS at 12 Months Is Associated with Improved Overall and Progression-Free Survival. the Randomized German CML-Study IV. Blood. 116(21). 669–669. 5 indexed citations
5.
Hanfstein, Benjamin, Martin C. Müller, Sebastian Kreil, et al.. (2010). Dynamics of mutant BCR-ABL-positive clones after cessation of tyrosine kinase inhibitor therapy. Haematologica. 96(3). 360–366. 36 indexed citations
6.
7.
Schleuning, Michael, Anja van Biezen, Arnon Nagler, et al.. (2010). Allogeneic Stem Cell Transplantation for Patients with Chronic Myeloid Leukemia After Prior Treatment with Nilotinib or Dasatinib. Blood. 116(21). 2348–2348. 1 indexed citations
8.
Leitner, Armin, Susanne Saußele, Claudia Haferlach, et al.. (2010). Impact of Variant t(9;22) and Additional Cytogenetic Aberrations at Diagnosis on Prognosis of CML. Blood. 116(21). 355–355.
9.
Rosée, Paul La, Armin Leitner, Philippe Martiat, et al.. (2009). Weekend Drug Holiday of Dasatinib in CML Patients Not Tolerating Standard Dosing Regimens. Reducing Toxicity with Maintained Disease Control.. Blood. 114(22). 1119–1119. 5 indexed citations
10.
Leitner, Armin, et al.. (2009). Betriebsärztliche Einleitung der Rehabilitationsmaßnahme und Begleitung der Rückkehr an den Arbeitsplatz. Physikalische Medizin Rehabilitationsmedizin Kurortmedizin. 19(4). 1 indexed citations
11.
Ernst, Thomas, Philipp Erben, Benjamin Hanfstein, et al.. (2008). ABL single nucleotide polymorphisms may masquerade as BCR-ABL mutations associated with resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemia. Haematologica. 93(9). 1389–1393. 41 indexed citations
12.
13.
Willeke, Frank, Karoline Horisberger, Uta Kraus-Tiefenbacher, et al.. (2007). A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer. British Journal of Cancer. 96(6). 912–917. 82 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Heather A. Bradeen Breakdown of academic impact, for papers by Jeiry Filian Breakdown of academic impact, for papers by Fabrizio Ciccone Breakdown of academic impact, for papers by Marie Colombat Breakdown of academic impact, for papers by J. Janssen Breakdown of academic impact, for papers by Julian Perez Ronco Breakdown of academic impact, for papers by J Score Breakdown of academic impact, for papers by U. Wandl Breakdown of academic impact, for papers by Mona Lisa Alattar Breakdown of academic impact, for papers by Arta Dreimane
Rankless by CCL
2026